Analysis of factors affecting progression-free survival of first-line chemotherapy in older patients with advanced gastrointestinal cancer

Junichi Nakazawa[a], Machiko Kawahira[b, c], Masahiro Kawahira[a], Tomoko Kodama[a], Shiho Arima[c], Yuji Iwashita[b], Seiji Mawatari[c], Shinichi Hashimoto[c], Shuji Kanmura[c], Takeshi Hori[b], Hirohito Tsubouchi[b], Akio Ido[c]

[a] Department of Medical Oncology, Kagoshima City Hospital, 37-1 Uearata-cho, Kagoshima city, Kagoshima, 890-8760, Japan

[b] Department of Gastroenterology, Kagoshima City Hospital, 37-1 Uearata-cho, Kagoshima city, Kagoshima, 890-8760, Japan

[c] Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima city, Kagoshima, 890-8520, Japan

E-mail:

Junichi Nakazawa: nakazawa-j87@kch.jagoshima.jp

Machiko Kawahira: k.machi0726@gmail.com

Masahiro Kawahira: kawahira-m50@kch.kagoshima.jp

Tomoko Kodama: ku.kodama.2020@gmail.com

Shiho Arima: sarima@m3.kufm.kagoshima-u.ac.jp

Yuji Iwashita: iwashita-y13@kch.kagoshima.jp

Seiji Mawatari: mawatari@m2.kufm.kagoshima-u.ac.jp

Shinichi Hashimoto: kumdsh@m.kufm.kagoshima-u.ac.jp

Shuji Kanmura: skanmura@m2.kufm.kagoshima-u.ac.jp

Takeshi Hori: hori-t71@kch.kagoshima.jp

Hirohito Tsubouchi: tsubouchi-h62@kch.kagoshima.jp

Akio Ido: ido-akio@m2.kufm.kagoshima-u.ac.jp

Corresponding author: Junichi Nakazawa

Department of Medical Oncology, Kagoshima City Hospital, 37-1 Uearata, Kagoshima city, Kagoshima, 890-8760, Japan

Tel.: +81-99-230-7000; Fax: +81-99-230-7070

E-mail: nakazawa-j87@kch.kagoshima.jp

Abstract

Objectives: There are many reports on the usefulness of predicting adverse events in geriatric assessment (GA) among older patients with cancer undergoing chemotherapy. However, few studies have investigated factors influencing the efficacy of chemotherapy for older patients with cancer. This study aimed to evaluate the usefulness of G8, GA, and factors measured in general clinical practice for evaluating progression-free survival (PFS) of first-line palliative chemotherapy in older patients with advanced gastrointestinal cancer.

Materials and Methods: This was a prospective observational study of older patients (age ≥ 70 years) with advanced gastrointestinal cancer. The modified cut-off value of G8 was determined by referencing to two or more abnormal GA conditions. The usefulness of baseline GA and G8 (conventional and modified cut-off value) was assessed according to the efficacy (PFS and disease control rate) of the administered first-line palliative chemotherapy.

Results: Overall, 93 patients were evaluated between March 2017 and February 2019. A modified G8 cut-off value of ≤ 12 had a sensitivity and specificity of 68.9% and 46.9%, respectively. PFS was significantly prolonged in the patients with G8 > 12, serum albumin ≥ 3.5 g/dl, and in whom grade ≥ 3 adverse events occurred. GA was not useful for predicting PFS prolongation or the occurrence of serious adverse events in first-line treatment.

Conclusion: Among older patients with advanced gastrointestinal cancer who undergo first-line chemotherapy, a modified G8 cutoff value of ≤ 12 could predict PFS.

Keywords: geriatric assessment, vulnerabilities screening tool, gastrointestinal cancer, first-line palliative chemotherapy

Introduction

The population of older patients with cancer has markedly increased in developed countries owing to the aging of the population, including in Japan. However, older patients are underrepresented in cancer clinical trials[1,2]. Although older patients are enrolled, their number is inadequate to generalize the results in the overall older population. Moreover, ageing is associated with various physiological changes that cannot be evaluated only by chronological age, with the older population being heterogeneous. Thus, the treatment of older patients with cancer requires a more individualized approach.

Geriatric assessment (GA) is useful for clarifying the problems specific to older patients and those that are often missed in routine clinical practice. Interventions for GA-identified vulnerabilities prolong prognosis and enable living at home[3]. Hurria et al reported that GA is more useful than the Eastern Cooperative Oncology Group Performance Status (ECOG PS) score for predicting chemotherapy-associated severe adverse events in older patients with cancer [4,5]. However, GA is time-consuming and is thus underutilized in clinical practice[6]. Therefore, a screening tool (ST) that can be performed more quickly and easily than GA has been developed[7-10]. The G8 Questionnaire (G8) is one of the most widely performed ST. It enables a holistic assessment by including several factors such as body mass index (BMI), loss of appetite, and weight loss. A G8 score of ≤ 14 indicates vulnerabilities, but the G8 score may vary greatly depending on the country, race, and cancer site[11,12,13]. In a Japanese study in whom majority of the patients had gastrointestinal cancer, dividing the G8 score to three groups (< 11, 11–14, ≥ 14) was useful for predicting prognosis[14]. G8 is generally used to screen out patients who do not need to undergo GA. However, even G8 is not routinely used in the clinical management of older patients with cancer owing to limited human and time resources.

Many studies of GA for older patients with cancer undergoing chemotherapy have been conducted in various cancer types

and treatment settings, and thus heterogeneous populations were analyzed. Accordingly, the results have shown that the usefulness of GA differs depending on the cancer type[15,16,17]. Statistical data in 2017 showed that 75% of cancer deaths in Japan are in patients aged ≥ 70 years, and half of these deaths are due to gastrointestinal cancer[18]. The goal of chemotherapy for advanced gastrointestinal cancer is symptomatic relief and survival while avoiding fatal adverse events, and thus highly effective regimens are needed. However, although the opportunities for chemotherapy for older patients with gastrointestinal cancer are increasing, the prognosis of advanced gastrointestinal cancer remains poor even with intensive chemotherapy. As such, it is important to determine the efficacy of chemotherapy before its initiation in older patients.

This study was conducted to identify a simpler method than GA for evaluating older patients with cancer, particularly those admitted to general hospitals with fewer resources. Specifically, we aimed to validate the usefulness of G8 in comparison to that of GA, and we evaluated the performance of baseline ST according to its sensitivity and specificity compared to that of baseline GA as a reference assessment for older patients with advanced gastrointestinal cancer aged ≥ 70 years who received first-line palliative chemotherapy.

Materials and Methods

Study design and patients

This prospective observational study was approved by the ethics committee of Kagoshima City Hospital and was conducted according to the 1964 Helsinki Declaration and its later amendments. Written informed consent to participate in the study was obtained after the chemotherapy regimen was determined by the attending physician, and then G8 was performed by the attending physician. GA was mainly performed by a clinical research associate before the start of treatment and the

results of GA were not known to the attending physician. The subjects were older patients (i.e., aged ≥ 70 years) with advanced gastrointestinal cancer admitted at our hospital. They were recruited between March 2017 and February 2019 according to the following eligibility criteria: (1) ECOG PS score of 0 to 2 and (2) eligibility for first-line palliative chemotherapy.

Treatment and assessment

The treatment regimen was selected by the attending physician according to the established standard treatment guidelines for each cancer type. The regimen of bevacizumab plus fluoropyrimidine therapy for colorectal cancer was defined as monotherapy. There were thirteen patients with locally advanced esophageal cancer who received chemoradiotherapy as first-line treatment. G8 was used as ST. Specifically, G8[19] was used to evaluate overall vulnerabilities. GA included the following seven geriatric conditions: (1) activities of daily living (ADL) as assessed using the Barthel Index (cut-off score < 100)[21]; (2) instrumental ADLs as assessed using the guidelines by Lawton and Brody (cut-off score < 5 items for men and < 8 items for women)[22]; (3) polypharmacy, which was defined as abnormal if 5 or more numbers of medications were taken per day; (4) mood as assessed using the Geriatric Depression Scale-15 (cut-off score for depression, > 5)[23]; (5) cognition as assessed using the Mini-Mental State Examination (MMSE) (cut-off score for cognitive impairment, < 24)[24]; (6) comorbidity as assessed using the updated version of Charlson Comorbidity Index (CCI) (cut-off score of ≥ 1 points)[25]; and (7) nutritional status as assessed using the BMI (cut-off score for undernutrition, < 20 kg/m^2). Considering the large influence of nutritional status in gastrointestinal cancer, the baseline albumin level (cut-off for undernutrition: < 3.5 g/dl) and percentage of unintentional weight loss in the 3 last months (cut-off score for undernutrition: > 3 kg) were added as a reference for evaluation of nutritional status.

Frailty was defined as two or more abnormalities in the seven geriatric conditions[9], and this definition was used to determine the optimal cutoff value of G8 in our study. All patients underwent G8 assessment by their attending physician before treatment initiation. Treatment-related toxicity was graded according to the Common Toxicity Criteria Adverse Event version 4[27]. Treatment response among patients with measurable lesions was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Meanwhile, treatment response was evaluated by clinical judgment in those without measurable lesions. All evaluations were conducted when the best effect was observed at all time points measured during the observation period.

Statistical analysis

The chi-square test was used to assess differences between categories. Fisher's exact test was used in the analysis in which the expected value of the sample was less than ten. Univariate binary logistic regression analysis was performed to investigate the association between baseline characteristics and disease control rate of first-line chemotherapy, grade ≥ 3 adverse events, or grade ≥ 3 adverse events requiring unplanned hospitalization. Covariates with a p-value < 0.05 in the univariable analysis were included in the multivariable analysis. The significant predictive factors of progression-free survival (PFS) from first-line chemotherapy were identified by generating Kaplan-Meier survival plots. PFS was calculated from the date of registration of our study to the date of disease progression. The Cox proportional hazards model was used to estimate the effect of baseline factors on PFS. Based on two or more geriatric conditions in GA as the reference test, the area under the receiver operating characteristic (AUROC) curve was used to determine the optimal cut-off score of G8 using the Youden index. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS®) version 24.0 (IBM, Armonk, NY, USA). A p value of < 0.05 was considered statistically significant.

Results

Patient characteristics

Initially, 94 patients consented to participation, but one patient withdraw consent, and thus 93 patients were included in the analysis. The patients' baseline characteristics are listed in Table 1. The median length of follow-up for the censored cases was 7.8 months (3 or more: 27.2 months) as of June 30, 2019. The median age was 76 years, and 36 patients were female (38.7%). In total, 65 and 28 patients had an ECOG PS score of 0 and 1-2, respectively. Most of the patients had distant metastases (n = 40, 43%) or postoperative recurrence (n = 24,26%). There were three patients with recurrence after definitive chemoradiotherapy for esophageal cancer. Thirteen patients with locally advanced esophageal cancer underwent chemoradiotherapy as first-line treatment.

Screening tool and geriatric assessment at baseline

The results from the ST are listed in Table 2-1. The median G8 score was 11 points, and 76 patients (81.7%) were considered to be frail based on the G8 conventional cut-off value of ≤ 14. The results from the GA are listed in Table 2-2. The most common geriatric condition was polypharmacy (n = 46, 49.5%). Cognitive impairment (n = 9, 9.7%) was less prevalent. Ten patients had no geriatric condition.

Diagnostic accuracy of G8

When two or more abnormalities were defined as vulnerable in the seven-item elderly function evaluation, the G8 cut-off value of ≤ 14 had a sensitivity of 88.5%; specificity, 31.3%; negative predictive value, 58.8%; and positive predictive value, 71.1%. Using two or more geriatric conditions as the reference test, the area under the curve (AUC) was 0.66, and the

optimal cut-off value of G8 was 11.5 as identified using the Youden index (Figure 1). When the cut-off value was set to ≤ 12, the sensitivity was 70.0%; specificity, 46.9%; negative predictive value, 44.1%; and positive predictive value, 71.2%.

Efficacy

The median PFS was 5.7 months (95% CI: 4.6-6.8) in the overall cohort. The results of multivariable Cox regression analysis for PFS for geriatric assessment and other factors at baseline are shown in Table 3. The median PFS was 4.8 months (95% CI: 4.1-5.5) in the group with G8 ≤ 12, whereas it was 9.5 months (95% CI: 5.8-13.2) in the group with G8 > 12 (HR: 2.023, 95% CI: 1.22-3.36; p = 0.006).

The patients who experienced grade ≥ 3 adverse events during first-line chemotherapy had longer PFS than those who did not experience these events (HR: 0.532, 95% CI: 0.31-0.91; p = 0.020). There was no significant correlation between adverse events requiring hospitalization and PFS (HR: 1.381; 95% CI: 0.854-2.232; p = 0.188).

Age (< 80 years vs ≥ 80 years [HR: 1.069, 95% CI: 0.653-1.750; p = 0.791]), sex (male vs female [HR: 1.009, 95% CI: 0.794-1.282; p = 0.941]), ECOG PS score (0 vs 1-2 [HR: 1.367; 95% CI: 0.824-2.267; p = 0.226]), cognitive impairment (MMSE score [HR: 0.987; 95% CI: 0.450-2.168; p = 0.974), therapy (doublet vs mono [HR: 1.404; 95% CI: 0.875-2.254; p = 0.162]), conventional cut-off G8 (> 14 vs ≤ 14 [HR: 1.404; 95% CI: 0.776-2.541; p = 0.261]), abnormal geriatric conditions (< 2 vs ≥ 2 [HR: 1.435; 95% CI: 0.880-2.340; p = 0.147]), and site of cancer (non CRC vs CRC [HR: 0.995; 95% CI: 0.580-1.707; p = 0.986]) were also not significantly associated with PFS. Meanwhile, dose reduction (no vs yes [HR: 1.554; 95% CI: 0.973-2.483; p = 0.065]) and stage (localized vs metastases or recurrence [HR: 1.728; 95% CI: 0.993-3.006; p = 0.053]) tend to be associated with PFS.

Patients with higher serum albumin (≥ 3.5 g/dl at baseline) had longer PFS than those with lower serum albumin (< 3.5 g/dl at baseline) (HR: 2.152, 95% CI: 1.295-3.754; p = 0.003).

The overall response rate (ORR) and disease control rate (DCR) in patients with and without measurable lesions are shown in Table 4. In patients with measurable disease, the DCR was significantly different by ECOG PS (0 VS 1 or 2), G8 (cut-off values: 12), IADL (normal vs abnormal), CCI (low vs medium), serum albumin at baseline (≥ 3.5 g/dl vs < 3.5 g/dl), and geriatric condition (< 2 conditions vs ≥ 2 conditions), and grade ≥ 3 adverse events (no vs yes). In multivariate analysis by factors with significant differences, only grade ≥3 adverse events (no vs yes) was significantly different (OR: 16.70, 95% CI: 3.007-92.64; p = 0.001).

Toxicity

Overall, 71 patients (76.3%) experienced grade ≥ 3 adverse events. One patient died of Takotsubo cardiomyopathy[28], and a possible treatment-related death could not be ruled out. Grade ≥ 3 hematologic and non-hematologic toxicities occurred in 33 (35.5%) and 57 (61.3%) patients, respectively (Table 5-1). The association of individual geriatric conditions, ST, and other baseline factors with grade ≥ 3 adverse events is shown in Table 5-2. GA and G8 (cut-off values: 14 or 12) were not significantly associated with grade ≥ 3 adverse events. Patients with an ECOG PS score of ≥ 1 experienced significantly more grade ≥ 3 adverse events than did patients with PS 0 (OR: 5.78, 95% CI: 1.249-26.73, p = 0.01). Patients with high CCI experienced significantly less grade ≥ 3 adverse events than did patients with normal group of updated CCI (odds ratio (OR): 0.315, 95% confidence interval (CI): 0.116-0.854, p = 0.02).

Meanwhile, there was no significant difference in the incidence of grade ≥ 3 adverse events by age (< 80 years vs ≥ 80 years), sex (male vs female), dose reduction at first administration (yes vs no), and chemotherapy regimen (doublet vs

mono). Patients with abnormal ADL (Barthel index) tended to experience grade ≥ 3 toxicities (OR: 3.11, 95% CI: 0.95-10.15, p = 0.052). The incidence of grade ≥ 3 adverse events tended to be lower in the group with cognitive impairment (MMSE > 24 points) than that in the group without cognitive impairment (MMSE ≤ 24 points) (OR: 0.269, 95% CI: 0.061-1.181, p = 0.067). This could be because only eight patients had cognitive impairment, and all but one had a caregiver to manage the occurrence of adverse events.

Discussion

Several studies have reported that GA is useful for assessing older patients indicated for chemotherapy. However, these studies often involved patients with various cancer types and treatment settings and predicted serious adverse events of chemotherapy, but rarely discussed about efficacy. The current study exclusively evaluated patients with unresectable gastrointestinal cancer and clarified whether GA, ST, and other factors at baseline could predict the efficacy of first-line palliative chemotherapy. We found no significant association between baseline factors (PS, G8, and GA) and the regimen (combination therapy or monotherapy) or the dose reduction of the first-line treatment. Patients with G8 score ≤ 12 were more likely to receive monotherapy (p = 0.06).

The Cancer and Aging Research Group score and the Chemotherapy Risk Assessment Scale for High-Age Patients score has been reported to be useful for predicting severe adverse events of chemotherapy in older patients with cancer[31,32]. However, these scoring systems are mainly used to predict grade ≥ 3 adverse events. Grade 4 hematologic toxicities do not always immediately lead to serious symptoms and can often be controlled with careful management even in older patients with cancer. Moreover, hematologic toxicities have been reported to be correlated with the efficacy of chemotherapy in various cancers[33]. Similarly, we found a prolonged PFS and significantly higher DCR in the patients who developed grade

≥ 3 adverse events. Meanwhile, although there was no significant difference in the group that experienced adverse events requiring hospitalization, the PFS was shorter than that in the group that was not hospitalized. (It is important to predict the possibility of serious symptoms, especially those requiring hospitalization, in older patients during chemotherapy.

In the current study, vulnerabilities could be ruled out in only 18% of the patients using the conventional G8 cut-off value of ≤ 14. However, when we used a cut-off value of ≤ 12, 37% of the patients were defined to be non-frail. A cut-off value of ≤ 12 could stratify PFS from first-line chemotherapy, whereas the conventional cut-off value of ≤ 14 points could not. Using a G8 cut-off value of ≤ 12, we could stratify the PFS from first-line chemotherapy, similar to that in a retrospective study[14]. The optimal G8 cut-off values may vary by cancer type, country, or clinical stage[11-13], and individual cut-offs may needed to better predict efficacy. G8 is useful for predicting overall survival[34-35], but not for severe adverse events such as grade ≥ 3 adverse events or those requiring hospitalization, regardless of the cut-off value in our study. This indicates that G8 could not substitute GA with respect to the prediction of severe adverse events. As Mohile et al. described in the ASCO guidelines, the screening tool may be useful for predicting prognosis rather than adverse events[30].

There were some limitations in our study. First, although we exclusively evaluated patients with gastrointestinal cancer, the cancer types vary widely. For example, the prognosis of pancreatic cancer and colorectal cancer seems to be significantly different However, in our study, there was no significant difference in PFS between colorectal cancer and other gastrointestinal cancers. Meanwhile, the prognosis in our study tended to differ according to stage, with the PFS being different between the localized group and the distant metastasis or recurrence group (HR: 1.728; 95% CI: 0.993-3.006; p = 0.053). Second, the treatment regimen varied between the patients, and no specific regimen was prescribed for each cancer type. Third, GA was primarily conducted by a clinical research associate or nurse after the attending physician screened the patient decided on a treatment regimen. Because the treatment is not specified in our study, it is probable that the treatment

intensity was decided according to the impression of the attending physician in charge at the first visit. It could be possible that a less aggressive treatment was prescribed to patients with a vulnerable impression. The reason for the significantly lower frequency of adverse events in patients with comorbidities was thought to be the tendency for less intense treatment (monotherapy for patients with low CCI score vs those with medium, high, and very high scores (OR: 2.00, 95% CI: 0.815-4.910, p = 0.128). Both PFS and DCR were significantly more effective in the group with grade ≥ 3 adverse events, and PFS tended to be shorter in the group with serious adverse events requiring hospitalization. This may mean that the appropriate intensity of treatment tailored to the individual patient will be beneficial during first-line treatment.

Conclusion

Among older patients with advanced gastrointestinal cancer who undergo first-line chemotherapy, a modified G8 cutoff value of ≤ 12 could predict PFS in first-line treatment. Among the factors evaluated in daily clinical practice, PS and albumin levels, rather than age or cancer site, were predictors of PFS prolongation. Low-intensity treatment to avoid the occurrence of adverse events can be detrimental.

Conflict of interest: none.

Author contributions

Study concepts: Junichi Nakazawa, Takeshi Hori, Hirohito Tsubouchi

Study design: Junichi Nakazawa

Data acquisition: Junichi Nakazawa, Machiko Kawahira, Masahiro Kawahira, Yuji Iwashita

Quality control of data and algorithms: Junichi Nakazawa, Machiko Kawahira, Masahiro Kawahira

Data analysis and interpretation: Junichi Nakazawa, Machiko Kawahira, Masahiro Kawahira

Statistical analysis: Junichi Nakazawa

Manuscript preparation: Junichi Nakazawa

Manuscript editing: Junichi Nakazawa, Takeshi Hori, Hirohito Tsubouchi

Manuscript review: All authors

Acknowledgments: We thank all the patients, their families, and all the investigators. We also thank the medical staff of the Department of Outpatient Chemotherapy in Kagoshima City Hospital.

Funding: none

Data statement: All data generated or analyzed during this study are included in this published article

References

[1] Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. *J Clin Oncol*. 2005;23(13):3112–3124. doi:10.1200/JCO.2005.00.141

[2] Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. *Cancer*. 2008;112(2):228–242. doi:10.1002/cncr.23157

[3] Rubenstein LZ, Stuck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. *J Am Geriatr Soc*. 1991;39(9 Pt 2):8S–18S. doi:10.1111/j.1532-5415.1991.tb05927.x

[4] Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. *J Clin Oncol*. 2011;29(25):3457–3465. doi:10.1200/JCO.2011.34.7625

[5] Hurria A, Mohile S, Gajra A, et al. Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer. *J Clin Oncol*. 2016;34(20):2366–2371. doi:10.1200/JCO.2015.65.4327

[6] Moth EB, Kiely BE, Stefanic N, et al. Oncologists' perceptions on the usefulness of geriatric assessment measures and the CARG toxicity score when prescribing chemotherapy for older patients with cancer. *J Geriatr Oncol*. 2019;10(2):210–215. doi:10.1016/j.jgo.2018.11.004

[7] Russo C, Giannotti C, Signori A, et al. Predictive values of two frailty screening tools in older patients with solid cancer: a comparison of SAOP2 and G8. *Oncotarget*. 2018;9(80):35056–35068. Published 2018 Oct 12. doi:10.18632/oncotarget.26147

[8] Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. *Ann Oncol*. 2015;26(2):288–300. doi:10.1093/annonc/mdu210

[9] Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. *Lancet Oncol*. 2012;13(10):e437–e444. doi:10.1016/S1470-2045(12)70259-0

[10] Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. *PLoS One*. 2014;9(12):e115060. Published 2014 Dec 11. doi:10.1371/journal.pone.0115060

[11] Greenlee H, Unger JM, LeBlanc M, Ramsey S, Hershman DL. Association between Body Mass Index and Cancer Survival in a Pooled Analysis of 22 Clinical Trials. *Cancer Epidemiol Biomarkers Prev*. 2017;26(1):21–29. doi:10.1158/1055-9965.EPI-15-1336

[12] Batai K, Murphy AB, Ruden M, et al. Race and BMI modify associations of calcium and vitamin D intake with prostate cancer. *BMC Cancer*. 2017;17(1):64. Published 2017 Jan 19. doi:10.1186/s12885-017-3060-8

[13] Jian-Cheng T, Shu-Sheng W, Bo Z, Jian F, Liang Z. Total laparoscopic right hemicolectomy with 3-step stapled intracorporeal isoperistaltic ileocolic anastomosis for colon cancer: An evaluation of short-term outcomes. *Medicine (Baltimore)*. 2016;95(48):e5538. doi:10.1097/MD.0000000000005538

[14] Takahashi M, Takahashi M, Komine K, et al. The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study. *PLoS One*. 2017;12(6):e0179694. Published 2017 Jun 22. doi:10.1371/journal.pone.0179694

[15] Spina M, Balzarotti M, Uziel L, et al. Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. *Oncologist*. 2012;17(6):838–846. doi:10.1634/theoncologist.2011-0417

[16] Aparicio T, Jouve JL, Teillet L, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. *J Clin Oncol*. 2013;31(11):1464–1470. doi:10.1200/JCO.2012.42.9894

[17] Brunello A, Basso U, Sacco C, et al. Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study. *Ann Oncol*. 2013;24(2):336–342. doi:10.1093/annonc/mds431

[18] Vital Statistics Japan (Ministry of Health, Labour and Welfare) *https://www.mhlw.go.jp › english › database › db-hw*

[19] Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. *Ann Oncol*. 2012;23(8):2166–2172. doi:10.1093/annonc/mdr587

[20] Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. *J Am Geriatr Soc*. 2003;51(10):1451–1454. doi:10.1046/j.1532-5415.2003.51465.x

[21] MAHONEY FI, BARTHEL DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. *Md State Med*

J. 1965;14:61–65.

[22] Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist*. 1969;9(3):179–186.

[23] Sheikh JI, Yesavage JA, Brooks JO 3rd, et al. Proposed factor structure of the Geriatric Depression Scale. *Int Psychogeriatr*. 1991;3(1):23–28. doi:10.1017/s1041610291000480

[24] Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189–198. doi:10.1016/0022-3956(75)90026-6

[25] Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011 Mar 15;173(6):676-82. doi: 10.1093/aje/kwq433. Epub 2011 Feb 17. PMID: 21330339.

[26] Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PMID: 19097774.

[27] CTCAE v4.0 – JCOG http://www.jcog.jp/doctor/tool/CTCAEv4J_20170912_v20_1.pdf

[28] Hamaker ME, Te Molder M, Thielen N, van Munster BC, Schiphorst AH, van Huis LH. The effect of a geriatric evaluation on treatment decisions and outcome for older cancer patients - A systematic review. *J Geriatr Oncol*. 2018;9(5):430–440. doi:10.1016/j.jgo.2018.03.014

[29] Owusu C, Koroukian SM, Schluchter M, Bakaki P, Berger NA. Screening older cancer patients for a Comprehensive Geriatric Assessment: A comparison of three instruments. *J Geriatr Oncol*. 2011;2(2):121-129. doi:10.1016/j.jgo.2010.12.002

[30] Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. *J Clin Oncol*. 2018;36(22):2326–2347. doi:10.1200/JCO.2018.78.8687

[31] Zhang J, Liao X, Feng J, Yin T, Liang Y. Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology. *Oncol Lett*. 2019;18(5):4947–4955. doi:10.3892/ol.2019.10840

[32] Lalami Y, Klastersky J. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data. *Crit Rev Oncol Hematol*. 2017;120:163–179. doi:10.1016/j.critrevonc.2017.11.005

[33] Agemi Y, Shimokawa T, Sasaki J, et al. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study. *PLoS One*. 2019;14(1):e0210499. Published 2019 Jan 17. doi:10.1371/journal.pone.0210499

[34] van Walree IC, Scheepers E, van Huis-Tanja L, et al. A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer. *J Geriatr Oncol*. 2019;10(6):847–858. doi:10.1016/j.jgo.2019.04.016

[35] Martinez-Tapia C, Paillaud E, Liuu E, et al. Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer. *Eur J Cancer*. 2017;83:211–219. doi:10.1016/j.ejca.2017.06.027

Table 1. Baseline characteristics of patients

Characteristic		n	%
Gender	Male	57	61.3%
	Female	36	38.7%
Age	Median	76 years	
	Range	70 - 88 years	
	70-74 years	37	39.8%
	75-79 years	24	25.8%
	80-84 years	22	23.7%
	85- years	10	10.8%
ECOG PS	0	65	69.9%
	1	20	21.5%
	2	8	8.6%
Current living situation	Lives alone	22	23.7%
	Lives with spouse, partner, or child	68	73.1%
	Residential care	3	3.2%
Tumor site	Esophagus	18	19.4%
	Stomach	11	11.8%
	Colorectal	22	23.7%
	Biliary tree	20	21.5%
	Pancreas	21	22.6%
	Peritoneum	1	1.1%
Stage	Localized	26	28.0%
	Metastatic	40	43.0%
	Recurrence*	27	29.0%
Chemotherapy	Mono	42	45.2%
	Doublet	51	54.8%

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status
Footnote:
Recurrence 3 patients after concurrent chemoradiotherapy for localaized esophageal cancer
24 patients after radical surgery

Table 2-1. Baseline assessment of screening tool (G8)

G8	median	score	11	
	mean		11.6	
	range		7 – 17	
	Normal (>14)		n=17	18.3%
	Abnormal (≤14)		n=76	81.7%

G8: G8 Questionnaire

Table 2-2. Baseline geriatric assessment

Instrument		n	%
Barthel Index	100 points	60	64.5
	< 100 points	33	35.5
IADL	normal ≥ 5 items for men and ≥ 8 items for women	65	70
	abnormal < 5 items for men and < 8 items for women	28	30.1
Polypharmacy	0 - 4 types of medication	47	50.5
	≥ 5 types of medication	46	49.5
GDS-15	< 5 points	69	74.2
	≥ 5 points	24	25.8
MMSE	≥ 24 points	85	91.4
	< 24 points	8	8.6
Updated CCI	low	65	69.9
	Medium, high, very high	28	30.1
Nutrition			
BMI	≥ 20	58	62.4
	< 20	35	37.6
Serum albumin	≥ 3.5 g/dl	65	69.9
	< 3.5 g/dl	28	30.1
Weight loss during the last 3 months	≤ 3kg	48	51.6
	> 3kg	45	48.4
Number of geriatric conditions	0	10	10.8
	1	17	18.3
	2	22	23.7
	3	19	20.4
	4 or greater	27	29.1

Abbreviations: IADL: instrumental activities of daily living, GDS-15: geriatric depression scale 15, MMSE: mini mental state examination, Updated CCI: updated version of Charlson comorbidity index, BMI: Body mass inde

Table 3. Multivariable Cox regression analysis for progression free survival for geriatric assessment and other factors at baseline

variable		Univariate analysis				Multivariate analysis			
		n=	HR	95% CI		p-value	HR	95% CI		p-value
Age	< 80 years	61	1							
	≥ 80 years	32	1.069	0.653	1.750	0.791				
Site of cancer	non CRC	71	1							
	CRC	22	0.995	0.580	1.707	0.986				
ECOG PS	0	65	1							
	1~	28	1.367	0.824	2.267	0.226				
Stage	localized	26	1							
	Rec / Mets	67	1.728	0.993	3.006	0.053				
G8	> 14 points	17	1							
	≤ 14 points	76	1.404	0.776	2.541	0.261				
	> 12 points	34	1							
	≤ 12 points	59	2.023	1.218	3.359	0.006	1.836	1.048	3.217	0.034
Barthel Index	100 points	60	1							
	< 100 points	33	0.939	0.576	1.53	0.801				
IADL	Normal	65	1							
	Abnormal	28	1.53	0.935	2.504	0.091				
Polypharmacy	0 - 4 types	47	1							
	5 ≥types	46	1.593	0.992	2.556	0.054				
GDS-15	< 5 points	65	1							
	≥ 5 points	28	1.462	0.872	2.452	0.15				
MMSE	> 24 points	85	1							
	≤ 24 points	8	0.873	0.376	2.03	0.753				
Updated CCI	low	65	1							
	Medium~	28	1.361	0.825	2.244	0.228				
BMI	≥ 20	58	1							
	< 20	35	1.242	0.766	2.013	0.38				

Serum albumin at baseline	≥ 3.5 g/dl	65	1							
	< 3.5 g/dl	28	2.152	1.295	3.574	0.003	1.805	1.041	3.131	0.036
Weight loss	≤ 3kg	48	1							
	> 3kg	45	1.489	0.929	2.387	0.098				
Geriatric condition	< 2 conditions	34	1							
	≥ 2 conditions	59	1.435	0.880	2.340	0.147				
Chemotherapy	doublet	50	1							
	mono	43	1.404	0.875	2.254	0.16				
Dose reduction	no	58	1							
	yes	35	1.554	0.973	2.483	0.065				
Grade ≥3 adverse events	no	22	1							
	yes	71	0.532	0.312	0.906	0.02	0.448	0.259	0.776	0.04
Grade ≥3 adverse events requiring	no	59	1							
hospitalization.	yes	34	1.381	0.854	2.232	0.188				

Abbreviations: G8: G8 Questionnaire, IADL: instrumental activities of daily living, GDS-15: geriatric depression scale 15, MMSE: mini mental state examination, Updated CCI: updated version of Charlson comorbidity index, BMI: Body mass index, non CRC: not colorectal cancer, CRC: colorectal cancer, Rec: Recurrence, Mets: Metastatic

Table 4-1. ORR, DCR in patients with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1)

	n = 85	%
ORR	22	25.9
DCR	60	70.6
Best overall response		
Complete response	0	0
Partial response	22	25.9
Stable disease	38	44.7
Progression disease	19	22.4
Not evaluated	6	7.1

Footnote: Stable disease without measurable disease: 7 patients. Progression disease without measurable disease: one patient

Abbreviations: DCR, disease control rate; ORR, objective response rate

Table 4-2. Association between baseline variables and DCR

variable		Univariate analysis				Multivariate analysis			
		n=	OR	95% CI	p-value	OR	95% CI		p-value
Age	< 80 years	44/59	1						
	≥ 80 years	15/26	0.465	0.176 1.231	0.120				
Site of cancer	CRC	12/21	1						
	Non CRC	47/64	2.074	0.743 5.790	0.986				
ECOG PS	0	46/59	1						
	1~	13/26	0.283	0.106 0.757	0.010	0.227	0.051	1.017	0.053
Stage	localized	15/21	1						
	Rec / Mets	44/64	0.880	0.298 2.602	0.817				
G8	> 14 points	13/17	1						
	≤ 14 points	46/68	0.643	0.188 2.202	0.480				
	> 12 points	29/34	1						
	≤ 12 points	30/51	0.246	0.082 0.741	0.009	0.304	0.073	1.259	0.101
Barthel Index	100 points	42/57	1						
	< 100 points	17/28	0.552	0.211 1.442	0.223				
IADL	Normal	46/60	1						
	Abnormal	13/25	0.330	0.123 0.884	0.025	0.774	0.196	2.830	0.664
Polypharmacy	0 - 4 types	32/43	1						
	5 ≥types	27/42	0.619	0.244 1.571	0.311				
GDS	< 5 points	45/60	1						
	≥ 5 points	14/25	0.424	0.159 1.133	0.083				
MMSE	> 24 points	55/78	1						
	≤ 24 points	4/7	0.558	0.116 2.691	0.462				
Updated CCI	low	45/58	1						
	Medium~	14/27	0.311	0.117 0.825	0.017	0.484	0.137	1.705	0.258
BMI	≥ 20	37/53	1						
	< 20	22/32	0.951	0.368 2.460	0.918				

Serum albumin at baseline	≥ 3.5 g/dl	47/62	1							
	< 3.5 g/dl	12/23	0.348	0.128	0.950	0.036	0.472	0.132	1.691	0.249
Weight loss	≤ 3kg	33/46	1							
	> 3kg	26/39	0.788	0.312	0.613	0.613				
Geriatric condition	< 2 conditions	29/33	1							
	≥ 2 conditions	30/52	0.188	0.058	0.613	0.003	0.339	0.059	1.944	0.225
Chemotherapy	doublet	37/50	1							
	mono	22/35	0.595	0.234	1.511	0.273				
Dose reduction	no	39/53	1							
	yes	20/32	0.598	0.234	1.533	0.283				
Grade ≥3 adverse events	no	8/19	1							
	yes	51/66	4.675	1.592	13.73	0.003	16.70	3.007	92.64	0.001
Grade ≥3 adverse events	no	39/53	1							
requiring hospitalization.	yes	20/32	0.598	0.234	1.533	0.283				

Abbreviations: G8: G8 Questionnaire, IADL: instrumental activities of daily living, GDS-15: geriatric depression scale 15, MMSE: mini mental state examination, Updated CCI: updated version of Charlson comorbidity index, BMI: Body mass index, non CRC: not colorectal cancer, CRC: colorectal cancer, Rec: Recurrence, Mets: Metastatic

Table 5-1. Summary of grade ≥3 adverse events

		n=93	
Grade 3-4 toxicity	Overall toxicity	71	76.3%
	Non-hematological toxicity	33	35.5%
	Non-hematological toxicity	58	62.4%
	Requiring hospitalization	34	36.6%

Table 5-2. Association between baseline variables and Grade 3-4 toxicity

	variable			Univariate analysis				Multivariate analysis			
		n=	%	OR	95% CI		p-value	OR	95% CI		p-value
Age	< 80 years	46 / 61	75.4	1							
	≥ 80 years	25 / 32	78.1	1.165	0.420	3.232	0.770				
ECOG PS	0	45 / 65	69.2	1							
	1~	26 / 28	92.9	5.778	1.249	26.73	0.010	6.145	1.287	29.34	0.023
G8	> 14 points	11 / 17	64.7	1							
	≤ 14 points	60 / 76	78.9	2.045	0.656	6.379	0.212				
	> 12 points	26 / 34	76.5	1							
	≤ 12 points	45 / 59	76.3	0.989	0.366	2.672	0.983				
Barthel Index	100 points	42 / 60	70.0	1							
	< 100 points	29 / 33	87.9	3.107	0.953	10.15	0.052				
IADL	no	51 / 65	78.5	1							
	yes	20 / 28	71.4	0.686	0.250	1.886	0.464				
Polypharmacy	0 - 4 types of medication	34 / 47	72.3	1							
	≥ 5 types of medication	37 / 46	80.4	1.57	0.596	4.143	0.358				
GDS-15	< 5 points	49 / 65	75.4	1							
	≥ 5 points	22 / 28	78.6	1.197	0.413	3.472	0.740				

MMSE	> 24 points	67 / 85	78.8	1							
	≤ 24 points	4 / 8	50.0	0.269	0.061	1.181	0.067				
Updated CCI	low	54 / 65	83.1	1							
	Medium, high, very high	17 / 28	60.7	0.315	0.116	0.854	0.020	0.295	0.104	0.842	0.022
BMI	≥ 20	41 / 58	70.7	1							
	< 20	30 / 35	85.7	2.488	0.826	7.494	0.099				
Serum albumin	≥ 3.5 g/dl	49 / 65	75.4	1							
	< 3.5 g/dl	22 / 28	78.6	1.197	0.413	3.472	0.740				
Weight loss	≤ 3kg	36 / 48	75.0	1							
	> 3kg	35 / 45	77.8	1.167	0.447	3.046	0.753				
Geriatric condition	< 2 conditions	25 / 34	73.5	1							
	≥ 2 conditions	46 / 59	78.0	1.274	0.478	3.393	0.628				
Chemotherapy	doublet	36 / 50	72.0	1							
	mono	34 / 43	79.1	1.608	0.600	4.309	0.343				
Dose reduction	no	43 / 58	74.1	1							
	yes	28 / 35	80.0	1.395	0.505	3.853	0.519				

Abbreviations: G8: G8 Questionnaire, IADL: instrumental activities of daily living, GDS-15: geriatric depression scale 15, MMSE: mini mental state examination, Updated CCI: updated version of Charlson comorbidity index, BMI: Body mass index

Figure 1



ROC curve for G8 with two or more geriatric conditions of GA as reference test. Footnote: For each point on the curve the G8 score ,sensitivity, specificity are indicated.

Abbreviations: ROC= Receiver operating characteristics

G8= G8 questionnaire

GA= geriatric assessment

Figure 2

A


Geriatric conditions < 3 (n=61)
Geriatric conditions >_3 (n=32)
Progression-free Survival
1.0
0.8
0.6
0.4
0.2
0.0
HR 1.872; 95% CI 1.152-3.042; p=0.011
.0
5.0
10.0
15.0
20.0
25.0
30.0
month

B


G8 > 12 (n=34)
G8 <_ 12 (n=59)
Progression-free Survival
1.0
0.8
0.6
0.4
0.2
0.0
HR 2.023; 95% CI 1.22-3.36;p=0.006
.0
5.0
10.0
15.0
20.0
25.0
30.0
month

C



Fig. 2 Kaplan-Meyer survival plots for progression-free survival.

A. Patients with less than three geriatric conditions versus patients with three or more geriatric conditions.
B. Patients with G8 >12 versus patients with G8 <_12.
C. Patients without grade 3-4 advised events versus patients with grade 3-4 advised events.